NEW YORK (GenomeWeb) — Response Genetics has been warned by Nasdaq that it is not in compliance with a rule to remain listing on the Nasdaq Capital Market, the company recently disclosed in a document filed with the US Securities and Exchange Commission.

Nasdaq sent a letter to the firm in late November saying it does not meet a listing requirement calling for a minimum of $2.5 million stockholders' equity. For the third quarter ended Sept. 30, Response Genetics had shareholders' equity of about $2.0 million, according to the firm's Form 10-Q. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.